\n<\/p>\n
February 02, 2026<\/p>\n
2 min read<\/p>\n<\/div>\n
\n\n\nAdd topic to email alerts\n<\/span>\n<\/p>\n\n\n\nReceive an email when new articles are posted on \n<\/p>\n\nPlease provide your email address to receive an email when new articles are posted on .<\/p>\n<\/div>\n<\/div>\n” data-action=subscribe>\nSubscribe\n<\/button>\n<\/div>\n<\/div>\n We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.<\/strong> <\/p>\nBack to Healio<\/button><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\nKey takeaways:<\/h2>\n\nCurrent methods of phantom limb pain relief are primarily focused on ameliorating symptoms.<\/li>\nThe Targeted Brain Rehabilitation platform allows for a neurological-based solution intended to rebuild neural pathways.<\/li>\n<\/ul>\nA neurological-based rehabilitation system to address phantom limb syndrome has been registered by the FDA as a Class II Software as a Medical Device, the manufacturer said in a press release.<\/p>\nThe Targeted Brain Rehabilitation (TBR), which is delivered via an immersive, hands-free virtual reality software platform, was developed by Axolo Health co-founders Glenn Gaston, MD,<\/b> and Bryan Loeffler, MD,<\/b> at the OrthoCarolina Reconstructive Center for Lost Limbs, according to the release. <\/p>\n\n\n<\/source><\/source><\/source><\/source><\/source><\/picture>\n<\/figcaption><\/figure>\n\u201cUp to 80% of amputees experience phantom limb pain, and many rely on long-term medications that manage symptoms without addressing the underlying neurological disruption,\u201d Gaston told Healio. \u201cAs surgeons caring for these patients over time, we saw the limits of existing options and the need for an approach that treated phantom limb pain as a brain-based condition rather than a peripheral one.\u201d<\/p>\nCurrent methods of phantom limb pain relief are primarily focused on ameliorating symptoms, rather than addressing the underlying neurological disruption, Axolo said in the release. As such, persistent phantom limb pain is likely to negatively impact ancillary issues such as prosthetic use, sleep quality and everyday function. By focusing on restoring disrupted neural pathways and retraining the brain, the TBR aims to support significant improvements in patient quality of life.<\/p>\n\u201cPhantom limb pain is distinct from residual limb pain and originates from changes in central nervous system processing after amputation,\u201d Loeffler told Healio. \u201cWhile residual limb pain can often be addressed through peripheral interventions, phantom limb pain reflects disrupted brain mapping and cortical reorganization.\u201d<\/p>\nReframing the condition under a neurology umbrella, he said, is essential to pursuing treatments that address the source of the pain rather than only its symptoms.<\/p>\nThe TBR software delivers a structured, four-phase therapeutic process grounded in established neurorehabilitation principles, Loeffler said. It begins with laterality recognition, followed by guided motor imagery, immersive mirror therapy and ultimately motor execution. <\/p>\nTogether, these phases are designed to retrain disrupted neural pathways by progressively restoring the brain\u2019s representation and control of the missing limb. As a result, TBR is intended to deliver consistent, repeatable neurorehabilitation in a clinical setting, Loeffler said.<\/p>\n<\/p>\nGlenn Gaston<\/b><\/p>\n<\/div>\n\u201cFDA registration allows TBR to be utilized in clinical settings through a regulated, standardized software system,\u201d Gaston told Healio. \u201cThis enables clinicians to integrate the therapy into real-world care pathways while ensuring consistency and oversight.\u201d<\/p>\nAxolo Health said it is currently commercializing the platform for in-clinic use, with plans to expand access over time as additional care settings are supported.<\/p>\nFor more information:<\/h2>\n Glenn Gaston, MD,<\/b> and Bryan Loeffler, MD<\/b>, <\/b>can be reached at neurology@healio.com.<\/p>\n
\nReceive an email when new articles are posted on \n<\/p>\n\nPlease provide your email address to receive an email when new articles are posted on .<\/p>\n<\/div>\n<\/div>\n” data-action=subscribe>\nSubscribe\n<\/button>\n<\/div>\n<\/div>\n We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.<\/strong> <\/p>\nBack to Healio<\/button><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\nKey takeaways:<\/h2>\n\nCurrent methods of phantom limb pain relief are primarily focused on ameliorating symptoms.<\/li>\nThe Targeted Brain Rehabilitation platform allows for a neurological-based solution intended to rebuild neural pathways.<\/li>\n<\/ul>\nA neurological-based rehabilitation system to address phantom limb syndrome has been registered by the FDA as a Class II Software as a Medical Device, the manufacturer said in a press release.<\/p>\nThe Targeted Brain Rehabilitation (TBR), which is delivered via an immersive, hands-free virtual reality software platform, was developed by Axolo Health co-founders Glenn Gaston, MD,<\/b> and Bryan Loeffler, MD,<\/b> at the OrthoCarolina Reconstructive Center for Lost Limbs, according to the release. <\/p>\n\n\n<\/source><\/source><\/source><\/source><\/source><\/picture>\n<\/figcaption><\/figure>\n\u201cUp to 80% of amputees experience phantom limb pain, and many rely on long-term medications that manage symptoms without addressing the underlying neurological disruption,\u201d Gaston told Healio. \u201cAs surgeons caring for these patients over time, we saw the limits of existing options and the need for an approach that treated phantom limb pain as a brain-based condition rather than a peripheral one.\u201d<\/p>\nCurrent methods of phantom limb pain relief are primarily focused on ameliorating symptoms, rather than addressing the underlying neurological disruption, Axolo said in the release. As such, persistent phantom limb pain is likely to negatively impact ancillary issues such as prosthetic use, sleep quality and everyday function. By focusing on restoring disrupted neural pathways and retraining the brain, the TBR aims to support significant improvements in patient quality of life.<\/p>\n\u201cPhantom limb pain is distinct from residual limb pain and originates from changes in central nervous system processing after amputation,\u201d Loeffler told Healio. \u201cWhile residual limb pain can often be addressed through peripheral interventions, phantom limb pain reflects disrupted brain mapping and cortical reorganization.\u201d<\/p>\nReframing the condition under a neurology umbrella, he said, is essential to pursuing treatments that address the source of the pain rather than only its symptoms.<\/p>\nThe TBR software delivers a structured, four-phase therapeutic process grounded in established neurorehabilitation principles, Loeffler said. It begins with laterality recognition, followed by guided motor imagery, immersive mirror therapy and ultimately motor execution. <\/p>\nTogether, these phases are designed to retrain disrupted neural pathways by progressively restoring the brain\u2019s representation and control of the missing limb. As a result, TBR is intended to deliver consistent, repeatable neurorehabilitation in a clinical setting, Loeffler said.<\/p>\n<\/p>\nGlenn Gaston<\/b><\/p>\n<\/div>\n\u201cFDA registration allows TBR to be utilized in clinical settings through a regulated, standardized software system,\u201d Gaston told Healio. \u201cThis enables clinicians to integrate the therapy into real-world care pathways while ensuring consistency and oversight.\u201d<\/p>\nAxolo Health said it is currently commercializing the platform for in-clinic use, with plans to expand access over time as additional care settings are supported.<\/p>\nFor more information:<\/h2>\n Glenn Gaston, MD,<\/b> and Bryan Loeffler, MD<\/b>, <\/b>can be reached at neurology@healio.com.<\/p>\n
” data-action=subscribe>\nSubscribe\n<\/button>\n<\/div>\n<\/div>\n We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.<\/strong> <\/p>\nBack to Healio<\/button><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\nKey takeaways:<\/h2>\n\nCurrent methods of phantom limb pain relief are primarily focused on ameliorating symptoms.<\/li>\nThe Targeted Brain Rehabilitation platform allows for a neurological-based solution intended to rebuild neural pathways.<\/li>\n<\/ul>\nA neurological-based rehabilitation system to address phantom limb syndrome has been registered by the FDA as a Class II Software as a Medical Device, the manufacturer said in a press release.<\/p>\nThe Targeted Brain Rehabilitation (TBR), which is delivered via an immersive, hands-free virtual reality software platform, was developed by Axolo Health co-founders Glenn Gaston, MD,<\/b> and Bryan Loeffler, MD,<\/b> at the OrthoCarolina Reconstructive Center for Lost Limbs, according to the release. <\/p>\n\n\n<\/source><\/source><\/source><\/source><\/source><\/picture>\n<\/figcaption><\/figure>\n\u201cUp to 80% of amputees experience phantom limb pain, and many rely on long-term medications that manage symptoms without addressing the underlying neurological disruption,\u201d Gaston told Healio. \u201cAs surgeons caring for these patients over time, we saw the limits of existing options and the need for an approach that treated phantom limb pain as a brain-based condition rather than a peripheral one.\u201d<\/p>\nCurrent methods of phantom limb pain relief are primarily focused on ameliorating symptoms, rather than addressing the underlying neurological disruption, Axolo said in the release. As such, persistent phantom limb pain is likely to negatively impact ancillary issues such as prosthetic use, sleep quality and everyday function. By focusing on restoring disrupted neural pathways and retraining the brain, the TBR aims to support significant improvements in patient quality of life.<\/p>\n\u201cPhantom limb pain is distinct from residual limb pain and originates from changes in central nervous system processing after amputation,\u201d Loeffler told Healio. \u201cWhile residual limb pain can often be addressed through peripheral interventions, phantom limb pain reflects disrupted brain mapping and cortical reorganization.\u201d<\/p>\nReframing the condition under a neurology umbrella, he said, is essential to pursuing treatments that address the source of the pain rather than only its symptoms.<\/p>\nThe TBR software delivers a structured, four-phase therapeutic process grounded in established neurorehabilitation principles, Loeffler said. It begins with laterality recognition, followed by guided motor imagery, immersive mirror therapy and ultimately motor execution. <\/p>\nTogether, these phases are designed to retrain disrupted neural pathways by progressively restoring the brain\u2019s representation and control of the missing limb. As a result, TBR is intended to deliver consistent, repeatable neurorehabilitation in a clinical setting, Loeffler said.<\/p>\n<\/p>\nGlenn Gaston<\/b><\/p>\n<\/div>\n\u201cFDA registration allows TBR to be utilized in clinical settings through a regulated, standardized software system,\u201d Gaston told Healio. \u201cThis enables clinicians to integrate the therapy into real-world care pathways while ensuring consistency and oversight.\u201d<\/p>\nAxolo Health said it is currently commercializing the platform for in-clinic use, with plans to expand access over time as additional care settings are supported.<\/p>\nFor more information:<\/h2>\n Glenn Gaston, MD,<\/b> and Bryan Loeffler, MD<\/b>, <\/b>can be reached at neurology@healio.com.<\/p>\n
Back to Healio<\/button><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\nKey takeaways:<\/h2>\n\nCurrent methods of phantom limb pain relief are primarily focused on ameliorating symptoms.<\/li>\nThe Targeted Brain Rehabilitation platform allows for a neurological-based solution intended to rebuild neural pathways.<\/li>\n<\/ul>\nA neurological-based rehabilitation system to address phantom limb syndrome has been registered by the FDA as a Class II Software as a Medical Device, the manufacturer said in a press release.<\/p>\nThe Targeted Brain Rehabilitation (TBR), which is delivered via an immersive, hands-free virtual reality software platform, was developed by Axolo Health co-founders Glenn Gaston, MD,<\/b> and Bryan Loeffler, MD,<\/b> at the OrthoCarolina Reconstructive Center for Lost Limbs, according to the release. <\/p>\n\n\n<\/source><\/source><\/source><\/source><\/source><\/picture>\n<\/figcaption><\/figure>\n\u201cUp to 80% of amputees experience phantom limb pain, and many rely on long-term medications that manage symptoms without addressing the underlying neurological disruption,\u201d Gaston told Healio. \u201cAs surgeons caring for these patients over time, we saw the limits of existing options and the need for an approach that treated phantom limb pain as a brain-based condition rather than a peripheral one.\u201d<\/p>\nCurrent methods of phantom limb pain relief are primarily focused on ameliorating symptoms, rather than addressing the underlying neurological disruption, Axolo said in the release. As such, persistent phantom limb pain is likely to negatively impact ancillary issues such as prosthetic use, sleep quality and everyday function. By focusing on restoring disrupted neural pathways and retraining the brain, the TBR aims to support significant improvements in patient quality of life.<\/p>\n\u201cPhantom limb pain is distinct from residual limb pain and originates from changes in central nervous system processing after amputation,\u201d Loeffler told Healio. \u201cWhile residual limb pain can often be addressed through peripheral interventions, phantom limb pain reflects disrupted brain mapping and cortical reorganization.\u201d<\/p>\nReframing the condition under a neurology umbrella, he said, is essential to pursuing treatments that address the source of the pain rather than only its symptoms.<\/p>\nThe TBR software delivers a structured, four-phase therapeutic process grounded in established neurorehabilitation principles, Loeffler said. It begins with laterality recognition, followed by guided motor imagery, immersive mirror therapy and ultimately motor execution. <\/p>\nTogether, these phases are designed to retrain disrupted neural pathways by progressively restoring the brain\u2019s representation and control of the missing limb. As a result, TBR is intended to deliver consistent, repeatable neurorehabilitation in a clinical setting, Loeffler said.<\/p>\n<\/p>\nGlenn Gaston<\/b><\/p>\n<\/div>\n\u201cFDA registration allows TBR to be utilized in clinical settings through a regulated, standardized software system,\u201d Gaston told Healio. \u201cThis enables clinicians to integrate the therapy into real-world care pathways while ensuring consistency and oversight.\u201d<\/p>\nAxolo Health said it is currently commercializing the platform for in-clinic use, with plans to expand access over time as additional care settings are supported.<\/p>\nFor more information:<\/h2>\n Glenn Gaston, MD,<\/b> and Bryan Loeffler, MD<\/b>, <\/b>can be reached at neurology@healio.com.<\/p>\n
A neurological-based rehabilitation system to address phantom limb syndrome has been registered by the FDA as a Class II Software as a Medical Device, the manufacturer said in a press release.<\/p>\n
The Targeted Brain Rehabilitation (TBR), which is delivered via an immersive, hands-free virtual reality software platform, was developed by Axolo Health co-founders Glenn Gaston, MD,<\/b> and Bryan Loeffler, MD,<\/b> at the OrthoCarolina Reconstructive Center for Lost Limbs, according to the release. <\/p>\n\n\n<\/source><\/source><\/source><\/source><\/source><\/picture>\n<\/figcaption><\/figure>\n\u201cUp to 80% of amputees experience phantom limb pain, and many rely on long-term medications that manage symptoms without addressing the underlying neurological disruption,\u201d Gaston told Healio. \u201cAs surgeons caring for these patients over time, we saw the limits of existing options and the need for an approach that treated phantom limb pain as a brain-based condition rather than a peripheral one.\u201d<\/p>\nCurrent methods of phantom limb pain relief are primarily focused on ameliorating symptoms, rather than addressing the underlying neurological disruption, Axolo said in the release. As such, persistent phantom limb pain is likely to negatively impact ancillary issues such as prosthetic use, sleep quality and everyday function. By focusing on restoring disrupted neural pathways and retraining the brain, the TBR aims to support significant improvements in patient quality of life.<\/p>\n\u201cPhantom limb pain is distinct from residual limb pain and originates from changes in central nervous system processing after amputation,\u201d Loeffler told Healio. \u201cWhile residual limb pain can often be addressed through peripheral interventions, phantom limb pain reflects disrupted brain mapping and cortical reorganization.\u201d<\/p>\nReframing the condition under a neurology umbrella, he said, is essential to pursuing treatments that address the source of the pain rather than only its symptoms.<\/p>\nThe TBR software delivers a structured, four-phase therapeutic process grounded in established neurorehabilitation principles, Loeffler said. It begins with laterality recognition, followed by guided motor imagery, immersive mirror therapy and ultimately motor execution. <\/p>\nTogether, these phases are designed to retrain disrupted neural pathways by progressively restoring the brain\u2019s representation and control of the missing limb. As a result, TBR is intended to deliver consistent, repeatable neurorehabilitation in a clinical setting, Loeffler said.<\/p>\n<\/p>\nGlenn Gaston<\/b><\/p>\n<\/div>\n\u201cFDA registration allows TBR to be utilized in clinical settings through a regulated, standardized software system,\u201d Gaston told Healio. \u201cThis enables clinicians to integrate the therapy into real-world care pathways while ensuring consistency and oversight.\u201d<\/p>\nAxolo Health said it is currently commercializing the platform for in-clinic use, with plans to expand access over time as additional care settings are supported.<\/p>\nFor more information:<\/h2>\n Glenn Gaston, MD,<\/b> and Bryan Loeffler, MD<\/b>, <\/b>can be reached at neurology@healio.com.<\/p>\n
\u201cUp to 80% of amputees experience phantom limb pain, and many rely on long-term medications that manage symptoms without addressing the underlying neurological disruption,\u201d Gaston told Healio. \u201cAs surgeons caring for these patients over time, we saw the limits of existing options and the need for an approach that treated phantom limb pain as a brain-based condition rather than a peripheral one.\u201d<\/p>\n
Current methods of phantom limb pain relief are primarily focused on ameliorating symptoms, rather than addressing the underlying neurological disruption, Axolo said in the release. As such, persistent phantom limb pain is likely to negatively impact ancillary issues such as prosthetic use, sleep quality and everyday function. By focusing on restoring disrupted neural pathways and retraining the brain, the TBR aims to support significant improvements in patient quality of life.<\/p>\n
\u201cPhantom limb pain is distinct from residual limb pain and originates from changes in central nervous system processing after amputation,\u201d Loeffler told Healio. \u201cWhile residual limb pain can often be addressed through peripheral interventions, phantom limb pain reflects disrupted brain mapping and cortical reorganization.\u201d<\/p>\n
Reframing the condition under a neurology umbrella, he said, is essential to pursuing treatments that address the source of the pain rather than only its symptoms.<\/p>\n
The TBR software delivers a structured, four-phase therapeutic process grounded in established neurorehabilitation principles, Loeffler said. It begins with laterality recognition, followed by guided motor imagery, immersive mirror therapy and ultimately motor execution. <\/p>\n
Together, these phases are designed to retrain disrupted neural pathways by progressively restoring the brain\u2019s representation and control of the missing limb. As a result, TBR is intended to deliver consistent, repeatable neurorehabilitation in a clinical setting, Loeffler said.<\/p>\n
Glenn Gaston<\/b><\/p>\n<\/div>\n
\u201cFDA registration allows TBR to be utilized in clinical settings through a regulated, standardized software system,\u201d Gaston told Healio. \u201cThis enables clinicians to integrate the therapy into real-world care pathways while ensuring consistency and oversight.\u201d<\/p>\n
Axolo Health said it is currently commercializing the platform for in-clinic use, with plans to expand access over time as additional care settings are supported.<\/p>\n
Glenn Gaston, MD,<\/b> and Bryan Loeffler, MD<\/b>, <\/b>can be reached at neurology@healio.com.<\/p>\n